机译:Bimekizumab在银屑病关节炎中的双IL-17A和IL-17F中和:来自临床前实验的证据和IL-17F有助于人类慢性组织炎症的随机安慰剂对照临床试验
UCB Pharma Global Exploratory Dev Slough Berks England;
Univ Amsterdam Dept Clin Immunol &
Rheumatol Amsterdam Netherlands;
UCB Pharma Struct Biol Slough Berks England;
UCB Pharma New Med Slough SL1 3WE Berks England;
UCB Pharma Immunol Patient Value Unit Brussels Belgium;
UCB Pharma Struct Biol Slough Berks England;
UCB Pharma New Med Slough SL1 3WE Berks England;
UCB Pharma Global Exploratory Dev Slough Berks England;
Nicolae Testemitanu State Univ Med &
Pharm Dept Rheumatol &
Nephrol Kishinev Moldova;
UCB Pharma Global Exploratory Dev Slough Berks England;
UCB Pharma Global Exploratory Dev Slough Berks England;
UCB Pharma Global Exploratory Dev Slough Berks England;
Univ Amsterdam Dept Clin Immunol &
Rheumatol Amsterdam Netherlands;
Univ Lyon Dept Clin Immunol &
Rheumatol Lyon France;
UCB Pharma New Med Slough SL1 3WE Berks England;
psoriatic arthritis; inflammation; cytokines; autoimmune diseases;
机译:Bimekizumab在银屑病关节炎中的双IL-17A和IL-17F中和:来自临床前实验的证据和IL-17F有助于人类慢性组织炎症的随机安慰剂对照临床试验
机译:患有活跃的患者的IL-17A和IL-17F的双重中和为:12周的第2B期研究结果
机译:患有活跃的患者的IL-17A和IL-17F的双重中和为:12周的第2B期研究结果
机译:扩展报告:Bimekizumab在银屑病关节炎中对IL-17A和IL-17F的双重中和作用:来自临床前实验和随机安慰剂对照临床试验的证据表明IL-17F有助于人类慢性组织炎症
机译:IL-17A和IL-17F的OP0231与Bimekizumab的双重中和有关患者报告的患者报告和生活质量结果的改善有关,患者有源强直性脊柱炎患者:2B相,随机,双盲,安慰剂控制的结果,剂量范围研究